Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Unicycive Therapeutics Inc (UNCY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: UNCY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $63.12
1 Year Target Price $63.12
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.29% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.96M USD | Price to earnings Ratio - | 1Y Target Price 63.12 |
Price to earnings Ratio - | 1Y Target Price 63.12 | ||
Volume (30-day avg) 7 | Beta 2 | 52 Weeks Range 2.02 - 11.00 | Updated Date 06/30/2025 |
52 Weeks Range 2.02 - 11.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.08% | Return on Equity (TTM) -92.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 62952910 | Price to Sales(TTM) 23.75 |
Enterprise Value 62952910 | Price to Sales(TTM) 23.75 | ||
Enterprise Value to Revenue 16.63 | Enterprise Value to EBITDA -1.03 | Shares Outstanding 12062900 | Shares Floating 7478895 |
Shares Outstanding 12062900 | Shares Floating 7478895 | ||
Percent Insiders 4.93 | Percent Institutions 49.6 |
Analyst Ratings
Rating 3 | Target Price 63.12 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Unicycive Therapeutics Inc
Company Overview
History and Background
Unicycive Therapeutics Inc. is a biopharmaceutical company focusing on developing and commercializing novel therapies for kidney diseases. Founded to address unmet needs in nephrology, it has advanced several clinical-stage programs.
Core Business Areas
- Renal Disease Therapies: Focuses on developing treatments for acute kidney injury, chronic kidney disease, and other related conditions.
Leadership and Structure
Details about the leadership team and organizational structure would need to be found through public sources (investor relations page).
Top Products and Market Share
Key Offerings
- Renazorb: A phosphate binding product to treat hyperphosphatemia in patients with Chronic Kidney Disease (CKD) on dialysis. Market share data is difficult to obtain without direct company reports. Competitors include Sanofi (Renvela/Renagel), Tricida (Velphoro), and Akebia Therapeutics (Auryxia).
- UNI-494: A Polycystin-1 inhibitor for treating autosomal dominant polycystic kidney disease (ADPKD). Market share data is not available as it is in development. Competitor is Tolvaptan.
Market Dynamics
Industry Overview
The renal disease market is substantial and growing due to the increasing prevalence of diabetes and hypertension, leading causes of kidney disease. It is characterized by a mix of established treatments and ongoing research for novel therapies.
Positioning
Unicycive Therapeutics is positioned as a company focusing on unmet needs in kidney disease, aiming to provide innovative treatments in hyperphosphatemia and ADPKD. Their competitive advantage relies on the efficacy and safety profiles of their products.
Total Addressable Market (TAM)
The TAM for CKD-related therapies is estimated in the billions of dollars globally. Unicycive's success depends on capturing a meaningful share of this market with its pipeline products.
Upturn SWOT Analysis
Strengths
- Focused on kidney disease therapies
- Clinical-stage pipeline
- Potential for novel treatments
Weaknesses
- Limited financial resources compared to larger pharma companies
- Reliance on successful clinical trial outcomes
- Limited commercialization experience
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new kidney disease indications
- Increasing prevalence of kidney disease
Threats
- Regulatory hurdles and delays
- Competition from established treatments
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- SNY
- AKBA
Competitive Landscape
Unicycive faces competition from established players and emerging companies in the kidney disease space. Success hinges on demonstrating superior efficacy and safety of their products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as it's a development-stage company.
Future Projections: Future growth depends heavily on successful clinical trial outcomes and regulatory approvals. Analyst estimates are needed for concrete projections.
Recent Initiatives: Recent initiatives include clinical trial advancements for Renazorb and UNI-494.
Summary
Unicycive Therapeutics is a biopharmaceutical company focused on kidney disease treatments. Its success hinges on the clinical trial outcomes of its pipeline products, particularly Renazorb and UNI-494. The company faces competition from larger pharmaceutical companies. Partnerships and regulatory approval are critical for Unicycive's future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports (unavailable real time)
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share data is estimated and may not be precise. The AI-based rating is for informational purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Unicycive Therapeutics Inc
Exchange NASDAQ | Headquaters Los Altos, CA, United States | ||
IPO Launch date 2021-07-12 | Founder, Chairman, CEO & President Dr. Shalabh K. Gupta M.D., MPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 22 | Website https://unicycive.com |
Full time employees 22 | Website https://unicycive.com | ||
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.